Methadone-induced torsades de pointes: A twist of fate

Heart and Lung: Journal of Acute and Critical Care

Volumn 40, Issue 5, 2011, Pages 448-453

  Thanavaro, Kristin L ^a   Thanavaro, Joanne L ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Cytochrome P450 inhibitors; Electrolyte abnormalities; Methadone; Prolonged QT interval; QT prolongation drugs; Torsads de points

Indexed keywords

BUPRENORPHINE; CYTOCHROME P450 INHIBITOR; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METFORMIN; METHADONE; METOPROLOL; MORPHINE SULFATE;

ADULT; ANEMIA; ARTICLE; CARDIAC PATIENT; CASE REPORT; DIABETES MELLITUS; DIZZINESS; DYSPNEA; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEROIN DEPENDENCE; HOSPITAL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; MALE; METHADONE TREATMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SMOKING; SYNCOPE; TELEMETRY; THORAX PAIN; TORSADE DES POINTES; URINE INCONTINENCE;

ANALGESICS, OPIOID; HEROIN DEPENDENCE; HUMANS; HYPOKALEMIA; MAGNESIUM DEFICIENCY; MALE; METHADONE; MIDDLE AGED; RISK FACTORS; TORSADES DE POINTES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80052264844     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2010.12.008     Document Type: Article

References (42)

1. Centers for Disease Control. Methadone maintenance treatment. The Academy for Educational Development (AED), IDU-related technical assistance is available to health departments funded by CDC to conduct HIV prevention and to HIV prevention community planning groups (CPGs). 2002:1-4. Available at: Accessed September 2010. http://www.cdc.gov/idu/facts/methadonefin.pdf.
2. Corkery J.M., Schifano F., Ghodse A.H., Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol 2004, 19:565-576.
3. Niveau G., Rougemont A.L., La Harpe R. Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983-1999. Eur J Public Health 2002, 12:224-227.
4. Weschules D.J., McMath J.A., Gallagher R., Alt C.J., Knowlton C.H. Methadone and the hospice patient: prescribing trends in the home-care setting. Pain Med 2003, 4:269-276.
5. Vastag B. Methadone regulations overhauled. JAMA 2001, 285:1435.
6. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., Mehler P.S. Torsade de pointes associated with very-high dose methadone. Ann Intern Med 2002, 137:501-504.
7. Sticherling C., Schaer B.A., Ammann P., Maeder M., Osswald S. Methadone-induced TdP tachycardias. Swiss Med Wkly 2005, 135:282-285.
8. Food and Drug Administration methadone alert (2006): death, narcotic overdose, and cardiac arrhythmias. Available at: Accessed October 30, 2010. http://paintopics.org/opioid_rx/methadone.php%23FDAadvisory.
9. Ehret G.B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., et al. Drug-induced long QT syndrome in injection drug users receiving methadone. Arch Intern Med 2006, 166:1280-1287.
10. Maremmani I., Pacini M., Cesaroni C., Lourecic M., Perugi G., Tagliamonte A. QT interval prolongation in patients on long-term methadone maintenance therapy. Eur Addic Res 2005, 11:44-49.
11. George S., Moreira K., Fapohunda M. Methadone and the heart: what the clinician needs to know. Curr Drug Abuse Rev 2008, 1:297-302.
12. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
13. Chan A., Isbister G.K., Kirkpatrick C.M., Dufful S.B. Drug induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. Q J Med 2007, 100:609-615.
14. European Agency for the Evaluation of Medical Products (EMEA) public statement to suspend the marketing authorization of Orlaam (levacetylmethadol) in the European Union. April 19, 2001.
15. Krantz M.J., Rowan S.B., Schmittner J., Bartelson B.B. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007, 26:79-85.
16. Al-Khatib S.M., Allen LaPointe N.M., Kramer J.M., Chen A.Y., Hammill B.G., Delong L., et al. A survey of health care practitioners' knowledge of the QT interval. J Gen Intern Med 2005, 20:392-396.
17. Martell B.A., Arnsten J.H., Krantz M.J. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005, 95:915-918.
18. Napolitano C., Priori S.G., Schwartz P.J. Torsade de pointes: mechanisms and management. Drugs 1994, 47:51-65.
19. Poluzzi E., Raschi E., Moretti U., De Ponti F. Drug induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009, 18:512-518.
20. Katchman A.N., Ebert S.N., McGroary K.A., Woosley R.L. Methadone blocks HERG current in transfected HEK cells. Pharmacologist 2001, 43:98. (Abstract).
21. Kurita T., Ohe T., Shimizu W., Hotta D., Shimomura K. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes. Pacing Clin Electrophysiol 1993, 16:33-38.
22. Huber A., Ling W., Fradis J., Charuvastra V.C. Comparison of the effects of methadone and LAAM on the electrocardiogram. Drug Alcohol Depend 2001, 63:S70.
23. Martell B.A., Arnsten J.H., Krantz M.J., Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005, 95:915-918.
24. Krantz M.J., Kutinsky I.B., Robertson A.D., Mehler P.S. Dose-related effects of methadone on QT prolongation in a series of patients with TdP. Pharmacotherapy 2003, 23:802-805.
25. Pearson E.C., Woolsey R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005, 14:747-753.
26. Bauman J.L., DiDomenico R.J. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther 2002, 7:195-202.
27. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., et al. Allelic variants in long-qt disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105:1943-1948.
28. Ackerman M.J., Tester D.J., Jones G.S., Will M.L., Burrow C.R., Curran M.E. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003, 78:1479-1487.
29. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985, 109:568-574.
30. Anderson N.E., Al-Khatib S.M., Roden D.M., Califf R.M. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002, 144:769-781.
31. Bazett H.C. An analysis of time-relations of electrocardiograms. Heart 1920, 353-370.
32. Abriel H., Schlapfer J., Keller D.I., Gavillet B., Buclin T., Biollaz J., et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly 2004, 134:685-694.
33. Bednar M.M., Harrigan E.P., Ruskin J.N. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002, 89:1316-1319.
34. Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003, 348:1866-1874.
35. Taylor D, Paton C, Kerwin R, eds. The Maudsley prescribing guidelines. 2005-2006. (8th ed). London: Taylor & Francis; 2005.
36. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006, 48:e247-e346.
37. Lamont P., Hunt S.C. A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med 2006, 21:C9-C12.
38. Patel A.M., Singh J.P., Ruskin J.N. Role of implantable cardioverter-defibrillators in patients with methadone-induced long QT syndrome. Am J Cardiol 2008, 101:209-211.
39. Stringer J., Welsh C., Tommasello A. Methadone-associated Q-T interval prolongation and Torsades de Pointes. Am J Health Syst Pharm 2009, 66:825-833.
40. Justo D., Gal-Oz A., Paran Y., Goldin Y., Zeltser D. Methadone associated TdP in opioid dependent patients. Addiction 2006, 101:1333-1338.
41. Krantz M.J., Martin J., Stimmel B., Mehta D., Haigney M.C.P. QTc interval screening in methadone treatment. Ann Intern Med 2009, 150:387-395.
42. Leavitt S.B., Krantz M.J. Cardiac considerations during MMT. Addict Treat Forum 2003, 1-6.